Showing results (241-250 of 441) with videos related to
Sort By:
Pageof 45
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02Roshan S Prabhu, Minhee Won, Edward G Shaw, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastomaTerri S Armstrong, Jeffrey S Wefel, Meihua Wang, et al.Neuro-Oncology Advances|May 29, 2026
Inhibition of chemokine CXCL12 modulates the tumor microenvironment in glioblastoma and potentiates immune checkpoint inhibitor efficacy in a tissue-specific mannerChen Makranz, Caitlin Huguely, Meili Zhang, et al.Journal of Neuro-Oncology|November 19, 2023
Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECTMackenzie Price, Corey Neff, Carol Kruchko, et al.Neuro-Oncology Practice|August 7, 2019
Association of genetic variants with fatigue in patients with malignant gliomaTerri S Armstrong, Elizabeth Vera, Renke Zhou, et al.Neuro-Oncology|March 8, 2011
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03Fabio M Iwamoto, Kathleen R Lamborn, John G Kuhn, et al.Cancer Genetics|February 27, 2019
RBM10 truncation in astroblastoma in a patient with history of mandibular ameloblastoma: A case reportNazanin K Majd, Nicolas R Metrus, Fernando Santos-Pinheiro, et al.Cancer Research|February 17, 2017
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA RepairYanxin Lu, Jakub Kwintkiewicz, Yang Liu, et al.Acta Neuropathologica Communications|July 10, 2020
High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymomaMark Raffeld, Zied Abdullaev, Svetlana D Pack, et al.Cancer Letters|December 5, 2017
LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiationWinson S Ho, Saman Sizdahkhani, Shuyu Hao, et al.Pageof 45